Exploratory Clinical Trial of Safety and Efficacy of Sacral Nerve Stimulation in Patients With Ulcerative Colitis.

An Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Sacral Nerve Stimulation in Patients

Although the incidence of inflammatory bowel disease is stable in North American and European countries, the incidence of inflammatory bowel disease is increasing in newly industrialized countries, especially in China. The treatment drugs for ulcerative colitis include 5-aminosalicylic acid (5-ASA), glucocorticoids, immunosuppressants, and biological agents.

The aim of this exploratory Clinical Trial is to evaluate the safety and efficacy of sacral nerve stimulation in patients with ulcerative colitis.

Inclusion Criteria:

• age ≥18 years
• ulcerative colitis diagnosed for at least 3 mouths.
• Mayo score 6-12, Mayo endoscopic score 2-3 points
• resistant to medical treatment

Exclusion Criteria:

• Treatment-naive ulcerative colitis (no previous treatment)
• Acute severe ulcerative colitis
• Currently taking any biologicals
• Previous surgical treatment or severe colitis at imminent risk of surgery
• infective colitis
• Other systemic diseases
• Pregnancy and lactation